<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04139395</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-49104</org_study_id>
    <nct_id>NCT04139395</nct_id>
  </id_info>
  <brief_title>68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)</brief_title>
  <official_title>68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carina Mari Aparici</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III study to evaluate 68Ga Citrate PET/MRI for detection of origin of fever
      of unknown origin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to evaluate a PET tracer (68Ga-Citrate) that can
      localize the origin of patients diagnosed with fever of unknown origin (FUO) using a PET/MRI
      scanner. We hope to learn if this can detect FUO better than with the present nuclear imaging
      standard of care (67Ga SPECT).

      We propose the following aim:

      â€¢ To evaluate 68Ga Citrate PET/MRI for detection of origin of fever in patients with fever of
      unknown origin.

      Patients disgnosed with fever of unknown origin are injected intravenously (IV) with 370 MBq
      of 68Ga Citrate. 45-60 minutes later, a whole body PET/MRI images are obtained.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uptake detected by investigational imaging agent</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The uptake detected on 68Ga Citrate PET/MRI and conventional 67Ga Citrate SPECT will be compared. Outcome will be reported as infectious uptake detected per patient for each imaging method.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Fever of Unknown Origin</condition>
  <arm_group>
    <arm_group_label>Diagnostic 68Ga-Citrate PET/MRI Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-Citrate PET/MRI</intervention_name>
    <description>Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.</description>
    <arm_group_label>Diagnostic 68Ga-Citrate PET/MRI Imaging</arm_group_label>
    <other_name>Gallium-68- Citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>67Ga-Citrate SPECT</intervention_name>
    <description>67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan</description>
    <arm_group_label>Diagnostic 68Ga-Citrate PET/MRI Imaging</arm_group_label>
    <other_name>Gallium-67- Citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Imaging with 68Ga-Citrate PET/MRI</description>
    <arm_group_label>Diagnostic 68Ga-Citrate PET/MRI Imaging</arm_group_label>
    <other_name>PET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Imaging with 68Ga-Citrate PET/MRI</description>
    <arm_group_label>Diagnostic 68Ga-Citrate PET/MRI Imaging</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>Medical Imaging, Magnetic Resonance/ Nuclear Magnetic Resonance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPECT</intervention_name>
    <description>Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.</description>
    <arm_group_label>Diagnostic 68Ga-Citrate PET/MRI Imaging</arm_group_label>
    <other_name>Single Photon Emission Computed Tomography/Computed Tomography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &gt;/=18 years old at the time of the scan.

          -  Patient with diagnosis of FUO.

          -  Patient is capable of complying with study procedures.

          -  Patient can remain still for duration of imaging procedure.

          -  Able to provide written consent.

        Exclusion Criteria:

          -  Patient is pregnant or nursing.

          -  Metallic implants (contraindicated for MRI).

          -  History of renal insufficiency (only for MRI contrast administration).

          -  Inability to lie still for the entire imaging time.

          -  Inability to complete the needed investigational and standard of care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.).

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the investigator, may significantly interfere
             with study compliance.

          -  Known allergy, hypersensitivity, or intolerance to the investigational product or its
             excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carina Mari Aparici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>clinical professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Risa Jiron, BS</last_name>
    <phone>(650)736-1598</phone>
    <email>rjiron@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Risa Jiron</last_name>
      <phone>650-736-1598</phone>
      <email>rjiron@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carina M Aparici, MD</last_name>
      <phone>(650)725-4711</phone>
      <email>drmari@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Carina Mari Aparici</investigator_full_name>
    <investigator_title>Clinical Professor, Radiology/ Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Fever of Unknown Origin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
    <mesh_term>Gallium citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

